Reversing Hypometabolic Symptoms by Normalizing Low Body Temperatures with Sustained-release T3 in Patients with Euthyroid TSH Levels
Denis E Wilson
PDF
HTML

Keywords

t3
sustained-release T3
cyclic t3
low body temperature
euthyroid
hypometabolism
fibromyalgia
reversible
PDF
HTML

Abstract

OBJECTIVE: Currently, the position of the American Thyroid Association is that hypothyroidism causes symptoms of metabolic slowing due to inadequate production of thyroid hormone by the thyroid gland; it is diagnosed by a lab result of a high thyroid stimulating hormone (TSH) level. While hypothyroidism is considered a chronic, incurable condition, the symptoms typically can be controlled by ingestion of thyroxine (T4) for life. Due to this conclusion, medical providers overall adhere to the assumption that people with normal TSH levels can not have thyroid-hormone-responsive symptoms; likewise, thyroid-hormone-responsive symptoms should not be treated with triiodothyronine T3 and are not reversible. Our objective was to examine if treatment with sustained-release (SR-T3), in patients with normal TSH values and low body temperatures, reduced symptoms consistent with low metabolic rate—and if improvement in symptoms remained even after discontinuation of the T3 treatment regimen.

INTERVENTIONS: We report the results of 11 euthyroid outpatients with low body temperatures who took oral SR-T3 every 12 hours according to a cyclic dosing schedule designed to titrate low body temperatures to normal. The SR-T3 they took was formulated with the aim of delivering the T3 gradually over 12 hours.

RESULTS: All of the patients in this study responded with an elevation in oral temperatures and improvement in five symptoms measured following the T3 treatment regimen.

CONCLUSION: Patients exhibiting hypometabolism with normal TSH levels may experience a reversal of symptoms with normalization of low body temperatures on administration of a sustained-release T3 regimen such that their symptoms remain improved after the regimen has been discontinued.

PDF
HTML

References

Merck Manuals. Vaginal Bleeding, http://www.merckmanuals.com/professional/gynecology_and_obstetrics/symptoms_of_gynecologic_disorders/vaginal_bleeding.html , ( 2010).
Davis A, Godwin A, Lippman J, et al. Triphasic Norgetimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol. 2000 Dec; 96(6):913–20.
Fraser IS. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust N Z J Obstet Gynaecol. 1990 Nov; 30(4):353–6.
Kurland GS, Hamolsky MW and Feedberg AS. Studiesin nonmyxedematous hypometabolism: The clinical syndrome and the effects of triiodothyronine, alone or combined with thyroxine. J. Clin Endocrinol 1955; 15:1354.
Refetoff S, Weiss RE and Usala SJ. The syndromes of resistance to thyroid hormone. Endocrinol Rev 1993; 14:348–99.
McDermott MT, et al. Subclinical Hypothyroidism Is Mild Thyroid Failure and Should be Treated J Clinical Endo & Meta 2001: 86 (10)4585–90.
Gillet M. Subclinical Hypothyroidism; Subclinical Thyroid Disease: Scientific Review and Guidelines for Diagnosis and Management. JAMA 2004; 291:228–38.
Felicetta J. Effects of Illness on Thyroid Function Tests. Postgrad Med 1989; 85: 213–20.
American Thyroid Association. http://www.thyroid.org/professionals/publications/statements/99_11_16_wilsons.html 2005.
Fields EM. Metabolic Stimulants-Reply, JAMA. 1957; 164(7):797–8.
Morton JH. Sodium Liothyronine in Metabolic Insufficiency Syndrome and Associated Disorder Prelim report. JAMA. 1957; 165(2):124–9.
Tittle RC. Effects of 3,5,3; L-Tri Iodothyronine in Patients with Metabolic Insufficiency Prelim Report. JAMA. 1956; 162(4):271–4.
Lam K.S., et al., Vasoactive intestinal peptide in the anterior pituitary is increased in hypothyroidism. Endocrinology, 1989; 124:1077–84.
Karkal S. Overcoming diagnostic and therapeutic obstacles in hypothyroidism. Emergency Medicine Reports, 1990; 11:219–27.
Lowe JC, Garrison RL, Reichman AJ, Yellin J, et al. Effectiveness and safety of t3 therapy for euthyroid fibromyalgia: a double-blind placebo-controlled crossover study. Clinical Bulletin Myofascial Ther 1997; 2:31–58.
Buchwald D, Garrity D. Comparison of patients with chronic fatigue syndrome, fibromyalgia, and multiple chemical sensitivities. Arch Intern Med 1994: 154(18)2049–53.
Lowe JC, Reichman AJ, Yellin J. The process of change during T3 treatment for euthyroid fibromyalgia: A double-blind placebo-controlled crossover study. Clin. Bull. Myofascial Ther., 1997; 2:91–124.
Sonkin LS. Myofascial pain due to metabolic disorders: diagnosis and treatment in Myofascial pain and Fibromyalgia: Trigger Point Management. Rachlin, ES (Ed.), 1994, Mosby: St Louis, MO, pp. 45–60.
Bunevicius R, Kazanavicius G, Zalinkevicius , et al. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999; 340: 424–9
Schimmel M and Utiger RD. Thyroidal and peripheral production of thyroid hormones. Review of recent findings and their clinical implications. Ann Intern Med 1977; 87: 760–8.
Refetoff S. Resistance to thyroid hormone: an historical overview. Thyroid 1994; 4: 345–9.
Scott LV, Svec F and Dinan T. A preliminary study of dehydroepiandrosterone response to low-dose ACTH in chronic fatigue syndrome and in healthy subjects. Psychiatry Res 2000; 97:21–8.
Gereben B. Cellular and Molecular Basis of Deiodinase-Regulated Thyroid Hormone Signaling. Endocr Rev 2008; 29(7): 898–938
Kaiser CA. In Vivo Inhibition of the 5’-Deiodinase Type II in Brain Cortex and Pituitary by Reverse Triiodothyronine. Endo 1986; 119(2) 762–70
Stojanovich L, Marisavljevich, D. et al. Stress as a trigger of autoimmune disease. Autoimmun Rev. 2008 Jan; 7(3):209–13
Martinez-Lavin M. Stress, the stress response, and fibromyalgia. Arth Research & Ther 2007; 9: 216
Joffe RT. Hormone treatment of depression. Dialogues Clin Neurosci. 2011 March; 13(1): 127–38
Cooper R, Lerer B. The use of thyroid hormones in the treatment of depression. Harefuah 2010 Aug; 149(8):529–34, 550, 549
Olfson M, Marcus SC. National Patterns in Antidepressant Medication Treatment. Arch Gen Psychiatry 2009; 66 (8): 848–56
Manning JS. What alternatives to first-line therapy for depression are effective? J Clin Psychiatry 2010; 71 Suppl 1:10–5
Abraham G, Milev R, Stuart Lawson J. T3 augmentation of SSRI resistant depression. J Affect Disord 2006 Apr; 91(2-3):211–5
Kelly T, Lieberman DZ. The use of triiodothyronine as an augmentation agent in treatment-resistant bipolar II and bipolar disorder NOS. J Affect Disord 2009 Aug; 116(3):222–6
Kelly T, Lieberman DZ. Long term augmentation with T3 in refractory major depression. J Affect Disord 2009 May; 115(1-2):230–3
Gold MS, Pottash ALC, Extein I. Hypothyroidism and Depression Evidence from Complete Thyroid Function Evaluation. JAMA 1981; 245(19): 1919–22
Johansson C, Thoren P. The effects of triiodothyronine(T3) on heart rate, temperature and ECG measured with telemetry in freely moving mice. Acta Physiol Scand. 1997 Jun; 1602):133–8.
Llewellyn-Smith IJ, Verberne AJM. Central Regulation of Autonomic Functions, Oxford Univ Press 2011
Friedman M. Supraphysiological Cyclic Dosing of Sustained Release T3 in Order to Reset Low Basal Body Temperature. PRHSJ 25(1) 23–9.
Wilson ED. Doctor’s Manual for Wilson’s Temperature Syndrome. Muskeegee Medical Publishing, 1991 p. 112
Ju RT, Nixon PR, Patel MV. Drug release from hydrophilic matrices. 1. New scaling laws for predicting polymer and drugrelease based on the polymer disentanglement concentration and the diffusion layer. J Pharm Sci. 1995 Dec; 84(12):1455–63.
DeLange F. The disorders induced by Iodine Deficiency. Thyroid, 1994; 4(1) 107–28
Ghent W, et al. Replacement in Fibrocystic Disease of the Breast. Can J Surg 1993; 36 453–60
Smyth PPA. Thyroid Disease and Breast Cancer. J Endocr Invest. 1993; 16:396–401
Van Den Eeden SK, Barzilay JI, Ettinger B and Minkoff J. Thyroid hormone use and the risk of hip fracture in women > or = 65 years: a case-control study. J Women’s Health 2003; 12:27–31.
Sijanaovic S and Karaner I. Bone loss in pre-menopausal women on long-term suppressive therapy with thyroid hormone. 2001, Medscape Women’s Health.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.